drugset / Trial / NCT03756090
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will look at effects the combination of palbociclib and dose-dense neoadjuvant chemotherapy may have on triple negative breast cancer tumours which have not yet been treated.
Timeline
- Start
- 2018-12-01
- Primary completion
- 2019-12-01
- Completion
- 2020-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Epirubicin | Small molecule | 90 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |